Open Access
| Issue |
BIO Web Conf.
Volume 174, 2025
2025 7th International Conference on Biotechnology and Biomedicine (ICBB 2025)
|
|
|---|---|---|
| Article Number | 02008 | |
| Number of page(s) | 7 | |
| Section | Innovations in Therapeutics and Disease Mechanisms | |
| DOI | https://doi.org/10.1051/bioconf/202517402008 | |
| Published online | 12 May 2025 | |
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492 [CrossRef] [PubMed] [Google Scholar]
- Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2019;28(10):1563-1579. doi:10.1158/1055-9965.EPI-19-0221 [CrossRef] [PubMed] [Google Scholar]
- Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446-454. doi:10.1038/nature25183 [CrossRef] [PubMed] [Google Scholar]
- Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ. 2005;330(7485):223. doi:10.1136/bmj.38308.477650.63 [CrossRef] [PubMed] [Google Scholar]
- Travis WD, Brambilla E, Riely GJ. New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials. J Clin Oncol. 2013;31(8):992-1001. doi:10.1200/JCO.2012.46.9270 [CrossRef] [PubMed] [Google Scholar]
- Govindan R, Page N, Morgensztern D, et al. Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database. J Clin Oncol. 2006;24(28):4539-4544. doi:10.1200/JCO.2005.04.4859 [CrossRef] [PubMed] [Google Scholar]
- Kagoya Y, Guo T, Yeung B, et al. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy. Cancer Immunol Res. 2020;8(7):926-936. doi:10.1158/2326-6066.CIR-18-0508 [CrossRef] [PubMed] [Google Scholar]
- Deuse T, Hu X, Agbor-Enoh S, et al. The SIRPα– CD47 immune checkpoint in NK cells. J Exp Med. 2021;218(3):e20200839. doi:10.1084/jem.20200839 [CrossRef] [PubMed] [Google Scholar]
- Hu X, Manner K, DeJesus R, et al. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. Nat Commun. 2023;14(1):2020. doi:10.1038/s41467-023-37785-2 [CrossRef] [PubMed] [Google Scholar]
- Hirabayashi K, Du H, Xu Y, et al. Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2(9):904-918. doi:10.1038/s43018-021-00244-2 [CrossRef] [PubMed] [Google Scholar]
- Huang S, Pan C, Lin Y, et al. BiTE‐Secreting CAR‐ γδ T as a Dual Targeting Strategy for the Treatment of Solid Tumors. Adv Sci. 2023;10(17):2206856. doi:10.1002/advs.202206856 [CrossRef] [Google Scholar]
- Li D, English H, Hong J, et al. A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer. Mol Ther - Oncolytics. 2022; 24: 849-863. doi: 10.1016/j.omto.2022.02.015 [CrossRef] [Google Scholar]
- Du H, Hirabayashi K, Ahn S, et al. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer Cell. 2019;35(2):221-237.e8. doi:10.1016/j.ccell.2019.01.002 [CrossRef] [PubMed] [Google Scholar]
- Shultz LD, Lyons BL, Burzenski LM, et al. Human Lymphoid and Myeloid Cell Development in NOD/LtSz- scid IL2R γ null Mice Engrafted with Mobilized Human Hemopoietic Stem Cells. J Immunol. 2005;174(10):6477-6489. doi:10.4049/jimmunol.174.10.6477 [CrossRef] [PubMed] [Google Scholar]
- Biradar S, Agarwal Y, Lotze MT, Bility MT, Mailliard RB. The BLT Humanized Mouse Model as a Tool for Studying Human Gamma Delta T Cell-HIV Interactions In Vivo. Front Immunol. 2022; 13: 881607. doi: 10.3389/fimmu.2022.881607 [CrossRef] [PubMed] [Google Scholar]
- Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology. 2016;2016(1):567-572. doi:10.1182/asheducation-2016.1.567 [CrossRef] [PubMed] [Google Scholar]
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447 [CrossRef] [PubMed] [Google Scholar]
- Santomasso BD, Park JH, Salloum D, et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2018;8(8):958-971. doi:10.1158/2159-8290.CD-17-1319 [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.